Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday
Palvella Therapeutics Inc PVLA
$139.04
▼ -7.42%
($-11.15)
⬇️ Below Yest. Low
🗓️ Earnings Next Week
Open
$147.61
Prev Close
$150.19
Day Range
$138.74 – $149.54
52W Range
$34.57 – $161.38
Market Cap
$1.99B
Beta
-0.20
EPS (TTM)
$-4.16
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-12-18 |
| Shares Out. | 14,340,000 |
| Website | palvellatx.com/ ↗ |
| Phone | 14842531461 |
| Employees | 29 |
| Net Income | -$15.8M |
| Total Assets | $263.8M |
| Total Liabilities | $31.4M |
| Equity | $232.3M |
About Palvella Therapeutics Inc
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Palvella Therapeutics Inc is a publicly traded company under the ticker symbol PVLA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)